Catalent Buying BMS Site in Italy

Catalent Buying BMS Site in Italy
Catalent Buying BMS Site in Italy

Continuing a buying spree that has added adding biologics and gene therapy capabilities to its manufacturing repertoire, California-based US drug developer Catalent is buying a biologics and oral dose form production site in Anagni, Italy, from pharmaceutical giant Bristol-Myers Squibb.

Terms of the deal expected to close by the end of 2019 were not disclosed.

The BMS facility with around 700 employees manufactures a wide variety of products including oncology and cardiology drugs, which Catalent in future will toll manufacture for the US drugmaker.

Catalent’a chief operating officer Alessandro Maselli said the 50-year-old facility will give his company advanced sterile drug product fill-finish and packaging capacity in Europe as well as established solid dose capabilities, isolator technology, automated inspection, packaging and warehousing and world class expertise in global product launches

For a number of years, BMS has used the site southeast of Rome as a primary launch facility for new medicines, and Catalent said it has a “demonstrated track record for innovation, efficiency and accelerated product launches.”

Anagni will complement Catalent’s existing European Biologics capabilities in Brussels, Belgium, which provides process development, sterile fill/finish and primary & secondary packaging for pre-filled syringe, and its clinical supply sites in the UK and Germany.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.